John Nosenzo - Apr 1, 2022 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Chief Commercial Officer
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Apr 1, 2022
Transactions value $
-$733,502
Form type
4
Date filed
4/5/2022, 09:14 PM
Previous filing
Feb 15, 2022
Next filing
Jun 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BVS Class A Common Stock Options Exercise +106K +245.3% 150K Apr 1, 2022 Direct F1, F2
transaction BVS Class A Common Stock Sale -$734K -66K -44.01% $11.12 83.9K Apr 4, 2022 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Restricted Stock Units Options Exercise $0 -106K -100% $0.00* 0 Apr 1, 2022 Class A Common Stock 106K Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2 Includes 40 shares acquired under the Company's 2021 Employee Stock Purchase Program on April 1, 2022.
F3 Reflects shares sold to cover taxes upon the vesting of RSUs on April 1, 2022 pursuant to a standing 10b5-1 instruction.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.48, inclusive. Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 The RSUs vested on April 1, 2022.